Physician profile
Joel A Hoffman
NPI 1639178486
$6,656.40
in general payments reported to CMS, 2019-2025
26 companies · $444 in 2025
The $444 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,198 · 2020: $868 · 2021: $554 · 2022: $2,424 · 2023: $613 · 2024: $554 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,612.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $2,820.32 | 2019-2025 | |
| Genzyme Corporation | $564.81 | 2019-2025 | |
| Intersect Ent, INC. | $500.78 | 2019-2021 | |
| Acclarent, INC | $456.61 | 2019-2022 | |
| Stryker Corporation | $417.90 | 2019-2025 | Scopis Ent |
| Inspire Medical Systems, INC. | $394.07 | 2022-2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $352.28 | 2019-2025 | Dupixent |
| Optinose US, INC. | $286.79 | 2019-2025 | |
| Glaxosmithkline, LLC. | $204.83 | 2019-2025 | Nucala |
| Kaleo, INC. | $112.31 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $99.64 | 2021 | |
| Allergan, INC. | $77.37 | 2020-2021 | |
| Neurent Medical Limited | $70.45 | 2022-2025 | Neuromark System, Neuromark Radiofrequency Console |
| Alk-Abello, INC | $42.43 | 2019-2024 | Grastek, Ragwitek, Odactra |
| Vertex Pharmaceuticals Incorporated | $33.23 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $30.20 | 2019-2021 | |
| Abbvie INC. | $27.18 | 2024 | |
| Smith+Nephew, INC. | $26.94 | 2024 | Coblation |
| Ars Pharmaceuticals Operations, INC. | $25.71 | 2025 | Neffy |
| Fortovia Therapeutics, INC. | $19.96 | 2019 | |
| Medtronic, INC. | $19.06 | 2024 | Propel |
| Arbor Pharmaceuticals, INC. | $16.71 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.85 | 2019 | |
| Hikma Pharmaceuticals USA | $15.73 | 2024 | Ryaltris |
| Olympus America INC. | $14.34 | 2019 | |
| Medtronic USA, INC. | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.